Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
SPECIAL ANNOUNCEMENT
2016 Photonics Buyers' Guide Clearance! – Use Coupon Code FC16 to save 60%!
share
Email Facebook Twitter Google+ LinkedIn Comments

Zeiss Says Sales of Lasers Top 500

Photonics.com
Jun 2000
DUBLIN, Calif., June 19 -- More than 500 Visulas 690s lasers have been sold since the US Food and Drug Administration (FDA) allowed the use of the laser in the activation of Visudyne, the therapy used to treat the wet form of age-related macular degeneration (AMD), Zeiss Humphrey Systems said.
Visudyne therapy is used for the treatment of AMD patients with predominantly classic subfoveal choroidal neovascularization. Only 10-15 percent of the estimated 500,000 people who get wet AMD every year are eligible for existing treatments. Medical experts estimate between 40-60 percent of all wet AMD cases will form predominantly classic lesions as the disease progresses; these lesions can cause blindness.


Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.